

## References

### S-222

1. Interqual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: The Indiana University experience. *J Clin Oncol.* 2017;35(10):1096-1102.
3. Lee S, Yamauchi T, Kinoshita K, Imamur S, Kamiya K. High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement. *J Clin Exp Hematop.* 2017;57(2):64-68.
4. Mousavi SA, Abedinzadeh N, Taj L, et al. Successful outcome of autologous stem cell transplantation for relapsed or refractory germ cell tumors. *Int J Hematol-Oncol Stem Cell Res.* 2018;12(3):191-195.
5. Oing C, Alsdorg W, vonAmsberg G, Oechsle K, Bokemeyer C. Platinum-refractory germ cell tumors: An update on current treatment options and developments. *World J Urol.* 2017;35:1167-1175.
6. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Testicular Cancer. Version 1.2022.
7. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Ovarian Cancer. Version 3.2021.
8. Zschäbitz S, Distler FA, Krieger B, et al. Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. 2018;9(32):22537-22545.
9. Ertürk İ, Yıldız B, Karadurmuş N, et al. Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation. *Gulhane Med J.* 2018;60(4):130-135.
10. Kilari D, D'Souza A, Fraser R, et al. Autologous hematopoietic stem cell transplantation for male germ cell tumors: Improved outcomes over 3 decades. *Biol Blood Marrow Transplant.* 2019;25(6):1099-1106.
11. Fergadis E, Gavrielatou N, Skouteris N, Athanasopoulos A, Lianos E, Kosmas C. Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor. *Anticancer Drugs.* 2019;30(2):205-208.

12. Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, Sweeney CJ. Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era. *Clin Genitourin Cancer*. 2019;17(1):58-64.e1.